Dornase Alfa
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00003 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | Epstein-Barr virus-associated mesenchymal tumor | KG + DL |
| 2 | metabolic disease due to other fatty acid oxidation disorder | KG + DL |
| 3 | megacystis-microcolon-intestinal hypoperistalsis syndrome | KG + DL |
| 4 | thiamine-responsive dysfunction syndrome | KG + DL |
| 5 | cataract associated with a metabolic disease | KG + DL |
| 6 | anodontia | KG + DL |
| 7 | vitamin B12- and folate-independent constitutional megaloblastic anemia | KG + DL |
| 8 | inborn disorder of branched-chain amino acid metabolism | KG + DL |
| 9 | metabolic disease with macular cherry-red spot | KG + DL |
| 10 | ciliopathy | KG + DL |
| 11 | nephrocalcinosis | KG + DL |
| 12 | encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 8 | KG + DL |
| 13 | microlissencephaly | KG + DL |
| 14 | malignant testicular Leydig cell tumor | KG + DL |
| 15 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | KG + DL |
| 16 | unexplained long-lasting fever/inflammatory syndrome | KG + DL |
| 17 | 5-oxoprolinase deficiency (disease) | KG + DL |
| 18 | immunodeficiency predominantly affecting antibody production | KG + DL |
| 19 | ear folding | KG + DL |
| 20 | arena syndrome | KG + DL |
| 21 | neuropathy, hereditary sensory and autonomic, adult-onset, with anosmia | KG + DL |
| 22 | monosomy 7 myelodysplasia and leukemia syndrome | KG + DL |
| 23 | nail-patella syndrome | KG + DL |
| 24 | AIDS phobia | KG + DL |
| 25 | succinic acidemia | KG + DL |
| 26 | qualitative or quantitative defects of calpain | KG + DL |
| 27 | X-linked spermatogenic failure | KG + DL |
| 28 | circadian rhythm sleep disorder, jet lag type | KG + DL |
| 29 | Sorsby’s fundus dystrophy | KG + DL |
| 30 | qualitative or quantitative defects of gamma-sarcoglycan | KG + DL |
| 31 | encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities | KG + DL |
| 32 | heart fibrosarcoma | KG + DL |
| 33 | melorheostosis | KG + DL |
| 34 | collagen 6-related myopathy | KG + DL |
| 35 | visceral steatosis, congenital | KG + DL |
| 36 | sickle cell-hemoglobin c disease syndrome | KG + DL |
| 37 | autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency | KG + DL |
| 38 | autosomal recessive distal myopathy | KG + DL |
| 39 | adult-onset autosomal dominant demyelinating leukodystrophy | KG + DL |
| 40 | choroid spindle cell melanoma | KG + DL |
| 41 | ataxia-hypogonadism-choroidal dystrophy syndrome | KG + DL |
| 42 | disease of receptor activity | KG + DL |
| 43 | channelopathy-associated congenital insensitivity to pain, autosomal recessive | KG + DL |
| 44 | cerebellar ataxia with peripheral neuropathy | KG + DL |
| 45 | otospondylomegaepiphyseal dysplasia, autosomal dominant | KG + DL |
| 46 | 46,XY disorder of sex development of endocrine origin | KG + DL |
| 47 | coloboma, ocular | KG + DL |
| 48 | malignant thyroid stimulating hormone producing neoplasm of pituitary gland | KG + DL |
| 49 | arterial tortuosity syndrome | KG + DL |
| 50 | inherited fatty acid metabolism disorder | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.